Lutetium (177 Lu) oxodotreotide

RED^1,2,3: NICE TA539 - treating unresectable or metastatic neuroendocrine tumours. (Decision date - September 2018)

To be used in line with NHSE commissioning intentions.

1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)